N/A
N=36
Potato Research for Enhancing Metabolic Outcomes
Insulin Resistance · Obesity
Bottom Line
View on ClinicalTrials.gov: NCT04203238 ↗Enrolled (actual)
36
Serious AEs
0.0%
Results posted
Nov 2023
Primary outcome: Primary: Glycemic Response to the Diet — -103.44; -501.91 mg/dL/min
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Reduced Meat High Potato Diet (Other); Reduced Meat High Pulses Diet (Other)
- Age
- Adult · 18+ yrs
- Sex
- All
- Sponsor
- Pennington Biomedical Research Center
- Primary completion
- May 2021
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Glycemic Response to the Diet |
-103.44; -501.91 | — |
| SECONDARY Insulin Response to the Diet |
-966.63; -2136.32 | — |
| SECONDARY Cholesterol Response to the Diet |
-5.01; -11.79 | — |
| SECONDARY Triglyceride Response to the Diet |
-4.67; -2.88 | — |
| SECONDARY LDL Particle Size Response to the Diet |
-0.27; -0.38 | — |
| SECONDARY hsCRP Response to the Diet |
0.51; 0.24 | <0.05 sig |
Summary
The potato is a nutritious food that comprises approximately 30% of total vegetable intake in the United States (US). Consumption of pulses in the US is low but its contribution to health is frequently promoted. However, in the US diet, potatoes contribute as much dietary fiber, far more potassium, and a host of similar nutrients as pulses. When prepared to enhance its slowly digested starch content, potatoes produce a moderate glycemic response. In encouraging a shift towards plant-based foods and sustainable diets, the potato can partially replace meat in meat dishes to enhance the overall quality of the diet and reduce meat intake to recommended levels.
Eligibility Criteria
Inclusion Criteria
- Adults from 18 - 60 years of age
- Body mass index between 25 and 40 kg/m2
- No evidence of diabetes (fasting blood sugar 2
- Willing to consume the study foods and refrain from eating other foods for eight weeks.
Exclusion Criteria
- Have type 1 or type 2 diabetes currently being treated by medication.
- Are being treated with medications that have a significant effect on insulin resistance, obesity, serum lipids, and metabolic rate, or medications that significantly increase body weight such as certain antidepressants, second-generation antipsychotics, systemic glucocorticoids, and adrenergic blockers or stimulators.
- Current pregnancy or breastfeeding.
- Women of childbearing potential who are not using an effective method of birth control (i.e., barrier method, intrauterine and cervical devices, oral contraceptives, hormonal injections (Depo Provera® ), condoms with spermicidal gel or foam, contraceptive patch (Ortho Evra), diaphragm, or abstinence), are not surgically sterilized (including tubal ligation and hysterectomy), or not at least two years postmenopausal. All women of childbearing potential will have a pregnancy test performed prior to starting the study treatment in each cohort. If a subject becomes pregnant during the study, they will be dropped from the study.
- Have clinically significant abnormal laboratory markers (as determined by the medical investigator).
- Have contraindications to participation in a diet intervention.
- Are unable to provide a baseline blood sample.
- Have any condition that impedes testing of the study hypothesis or makes it unsafe to consume the foods being tested in the study (determined by the investigative team).
Data sourced from ClinicalTrials.gov (NCT04203238). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.